Analysts expect Inhibikase Therapeutics, Inc. to report revenue of 0.00 for Q1 25, against a range of 0.00 to 0.00. The most recent reported quarter, Q2 26, came in at 0.00.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | - | 916,755.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | |||||||||||
| High Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 454,386.44 | 0.00 | 0.00 | 11,653.42 | 379,979.41 | 7.98 M | |||||||||||
| Low Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 378,229.56 | 0.00 | 0.00 | 9,892.20 | 339,350.91 | 6.71 M | |||||||||||
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 416,308.00 | 0.00 | 0.00 | 10,772.81 | 359,665.16 | 7.35 M |
Analysts expect Inhibikase Therapeutics, Inc. to report earnings per share of -0.12 for Q3 26, against a range of -0.13 to -0.11. The most recent reported quarter, Q2 26, came in at -0.11, a 10.0% miss against the -0.10 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.65 | 0.88 | -0.15 | -0.11 | -0.13 | -0.10 | -0.10 | -0.11 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -0.47 | -0.09 | -0.09 | -0.07 | -0.12 | -0.10 | -0.10 | -0.09 | -0.11 | -0.11 | -0.11 | -0.12 | -0.06 | 0.01 | -0.21 | -0.15 | ||||||||||
| Low Estimate | -0.53 | -0.11 | -0.11 | -0.09 | -0.14 | -0.10 | -0.12 | -0.11 | -0.13 | -0.13 | -0.13 | -0.14 | -0.06 | 0.01 | -0.23 | -0.17 | ||||||||||
| Consensus Estimate | -0.50 | -0.10 | -0.10 | -0.08 | -0.13 | -0.10 | -0.11 | -0.10 | -0.12 | -0.12 | -0.12 | -0.13 | -0.06 | 0.01 | -0.22 | -0.16 |
Pull Wall Street consensus for Inhibikase Therapeutics, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=IKT&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "IKT", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=IKT&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();